Vyndamax Dosage/Direction for Use

Posology: The recommended dose of VYNDAMAX is 61 mg tafamidis orally once daily (see Pharmacology: Pharmacodynamics under Actions).
VYNDAMAX can be taken with or without food.
A single 61 mg tafamidis capsule is bioequivalent to 80 mg tafamidis meglumine (four 20 mg tafamidis meglumine capsules). The two formulations are not interchangeable on a per mg basis (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Special populations: Paediatric: VYNDAMAX should not be prescribed in the paediatric population as transthyretin amyloidosis is not a disease present in this population.
Elderly: No dosage adjustment is required for elderly patients (≥65 years) (see Pharmacology: Pharmacokinetics under Actions).
Renal or hepatic impairment: No dosage adjustment is required for patients with renal impairment, or mild or moderate hepatic impairment. VYNDAMAX has not been studied in patients with severe hepatic impairment.
Method of administration: Oral use.
The capsule(s) should be swallowed whole and not crushed or cut.
VYNDAMAX may be taken with or without food.
If a dose is missed, the patient should take the dose as soon as remembered. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.